Entrada Therapeutics (TRDA) Net Income towards Common Stockholders (2022 - 2025)
Historic Net Income towards Common Stockholders for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.2 million.
- Entrada Therapeutics' Net Income towards Common Stockholders fell 21575.19% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28829.49%. This contributed to the annual value of $65.6 million for FY2024, which is 108780.3% up from last year.
- Per Entrada Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$44.2 million for Q3 2025, which was down 21575.19% from -$43.1 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Net Income towards Common Stockholders registered a high of $55.0 million during Q2 2024, and its lowest value of -$44.2 million during Q3 2025.
- Its 4-year average for Net Income towards Common Stockholders is -$9.4 million, with a median of -$17.3 million in 2025.
- In the last 5 years, Entrada Therapeutics' Net Income towards Common Stockholders surged by 44948.68% in 2024 and then plummeted by 21575.19% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' Net Income towards Common Stockholders stood at -$24.6 million in 2022, then soared by 61.43% to -$9.5 million in 2023, then surged by 111.63% to $1.1 million in 2024, then plummeted by 4098.19% to -$44.2 million in 2025.
- Its last three reported values are -$44.2 million in Q3 2025, -$43.1 million for Q2 2025, and -$17.3 million during Q1 2025.